The Combination of MK-2206 and WZB117 Exerts a Synergistic Cytotoxic Effect Against Breast Cancer Cells
Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in women. Hormone receptor-positive breast cancer is usually subjected to hormone therapy, while triple-negative breast cancer is more formidable and poses a therapeutic challenge. Glucose transporters a...
Main Authors: | Yu-Liang Li, Hao-Cheng Weng, Jui-Ling Hsu, Shu-Wha Lin, Jih-Hwa Guh, Lih-Ching Hsu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.01311/full |
Similar Items
-
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
by: Elizabeth H. Stover, et al.
Published: (2022-04-01) -
WZB117 Decorated Metformin-Carboxymethyl Chitosan Nanoparticles for Targeting Breast Cancer Metabolism
by: Anindita De, et al.
Published: (2023-02-01) -
Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
by: Anna Richter, et al.
Published: (2021-03-01) -
WZB117 enhanced the anti-tumor effect of apatinib against melanoma via blocking STAT3/PKM2 axis
by: Ren-Shu Zhang, et al.
Published: (2022-09-01) -
The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells
by: Hai-Ling Gao, et al.
Published: (2023-07-01)